Regeneron Pharmaceuticals Inc. buy Truist Financial Co.
Summary
This prediction is currently active. With a performance of 1.09%, the BUY prediction by Truist_Financial_Co_ for Regeneron Pharmaceuticals Inc. is trending in the right direction. This prediction currently runs until 26.03.25. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 8.074% | 8.074% |
iShares Core DAX® | 2.831% | 1.236% |
iShares Nasdaq 100 | 2.918% | 0.640% |
iShares Nikkei 225® | 2.007% | -2.135% |
iShares S&P 500 | 2.257% | 0.451% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Truist_Financial_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
03.04.24
03.04.25
07.05.24
Regeneron Pharmaceuticals Inc.
18.12.23
18.12.24
07.05.24
Regeneron Pharmaceuticals Inc.
28.11.23
28.11.24
07.05.24
Regeneron Pharmaceuticals Inc.
16.08.23
16.08.24
07.05.24